Rahmoune Hassan, Guest Paul C
Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, CB2 3RA, UK.
Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP), Campinas, SP, Brazil.
Methods Mol Biol. 2017;1546:3-17. doi: 10.1007/978-1-4939-6730-8_1.
Multiplex biomarker tests are becoming an essential part of the drug development process. This chapter explores the role of biomarker-based tests as effective tools in improving preclinical research and clinical development, and the challenges that this presents. The potential of incorporating biomarkers in the clinical pipeline to improve decision making, accelerate drug development, improve translation, and reduce development costs is discussed. This chapter also discusses the latest biomarker technologies in use to make this possible and details the next steps that must undertaken to keep driving this process forwards.
多重生物标志物检测正成为药物研发过程的重要组成部分。本章探讨了基于生物标志物的检测作为改善临床前研究和临床开发的有效工具的作用，以及由此带来的挑战。讨论了将生物标志物纳入临床流程以改善决策、加速药物研发、提高转化效率和降低研发成本的潜力。本章还讨论了为实现这一目标而使用的最新生物标志物技术，并详细说明了为推动这一进程必须采取的后续步骤。
